email   Email Us: phone   Call Us: +1 (914) 407-6109   57 West 57th Street, 3rd floor, New York - NY 10019, USA

Lupine Publishers Group

Lupine Publishers

  Submit Manuscript

ISSN: 2637-6679

Research and Reviews on Healthcare: Open Access Journal

Short Communication(ISSN: 2637-6679)

Why a Non-Metastatic Prostate Cancer Should Become a Castration Resistant Prostate Cancer?

Volume 4 - Issue 5

Francesco Carrozza1* and Matteo Santoni2

  • Author Information Open or Close
    • 1Medical Oncology Department of Romagna, Faenza Hospital, Italy
    • 2Medical Oncology, Macerata Hospital, Italy

    *Corresponding author: Francesco Carrozza, Medical Oncology Department of Romagna, Faenza Hospital, 48018, Viale Stradone 9 Faenza (Ravenna), Italy

Received: January 20, 2020;   Published: February 07, 2020

DOI: 10.32474/RRHOAJ.2020.04.000196

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF


The issue of resistance to the “hormonal deprivation control” in Prostate Cancer (PC), is one of the most common and problematic aspects of this disease. It is well known how, under hormonal deprivation, the PC tends to increase over time its threshold of tolerability to ever lower levels of testosterone (usually produced by the cancer itself through paracrine or autocrine mechanisms). The hormone sensitivity (HS) period of PC lasts about 2 years; therefore, the disease subsequently develops increasingly effective mechanisms of resistance to androgen deprivation therapy (ADT), which will transform it into castration-resistant PC (CRPC).

Short Communication|